Cardioprotective Effects of Mitochondria-Targeted Peptide SBT-20 in two Different Models of Rat Ischemia/Reperfusion

Cardiovascular Drugs and Therapy

Volumn 30, Issue 6, 2016, Pages 559-566

  Dai, Wangde ^a,b   Cheung, Elissa ^a   Alleman, Rick J ^c   Perry, Justin B ^c   Allen, Mitchell E ^c   Brown, David A ^c   Kloner, Robert A ^a,b  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cardioprotection; Mitochondria; Myocardial infarction; Peptide

Indexed keywords

CARDIOVASCULAR AGENT; HYDROGEN PEROXIDE; PEPTIDE; REACTIVE OXYGEN METABOLITE; SBT 20; SODIUM CHLORIDE; UNCLASSIFIED DRUG; CARDIOTONIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CORONARY REPERFUSION; DRUG MEGADOSE; FEMALE; HEART FUNCTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART PROTECTION; HEART RATE; LOW DRUG DOSE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANIMAL; CARDIAC MUSCLE; CELL RESPIRATION; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG EFFECTS; HEART; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PRESSURE; IN VITRO STUDY; MALE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; OXYGEN CONSUMPTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOTONIC AGENTS; CELL RESPIRATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEMALE; HEART; HYDROGEN PEROXIDE; IN VITRO TECHNIQUES; MALE; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXYGEN CONSUMPTION; PEPTIDES; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84991577792     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6695-9     Document Type: Article

References (23)

1. Kloner RA, Dai W, Hale SL, Shi J. Approaches to improving cardiac structure and function during and after an acute myocardial infarction: acute and chronic phases. J Cardiovasc Pharmacol Ther. 2016;21(4):363–7.
2. Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation. 2009;120(21):2105–12.
3. Goldhaber JI, Weis JN. Oxygen free radicals and cardiac reperfusion abnormalities. Hypertension. 1992;20:118–27.
4. Petrosillo G, Venosa ND, Pistolese M, et al. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia–reperfusion: role of cardiolipin. FASEB J. 2006;20:269–76.
5. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal. 2008;10(3):601–19.
6. Cho J, Won K, Wu D, et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18(3):215–20.
7. Frasier CR, Moukdar F, Patel HD, et al. Redox-dependent increases in glutathione reductase and exercise preconditioning: role of NADPH oxidase and mitochondria. Cardiovasc Res. 2013;98(1):47–55.
8. Brown DA, Hale SL, Baines CP, et al. Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia. J Cardiovasc Pharmacol Ther. 2014;19(1):121–32.
9. Kloner RA, Hale SL, Dai W, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Assoc. 2012;1(3):e001644.
10. Sloan RC, Moukdar F, Frasier CR, et al. Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J Mol Cell Cardiol. 2012;52(5):1009–18.
11. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 2011;435(2):297–312.
12. Alleman RJ, Tsang AM, Ryan TE, et al. Exercise-induced protection against reperfusion arrhythmia involves stabilization of mitochondrial energetics. Am J Physiol Heart Circ Physiol. 2016;310(10):H1360–70.
13. Krumschnabel G, Fontana-Ayoub M, Sumbalova Z, et al. Simultaneous high-resolution measurement of mitochondrial respiration and hydrogen peroxide production. Methods Mol Biol. 2015;1264:245–61.
14. Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431–5.
15. Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014;96(6):672–83.
16. Brown DA, Sabbah HN, Shaikh SR. Mitochondrial inner membrane lipids and proteins as targets for decreasing cardiac ischemia/reperfusion injury. Pharmacol Ther. 2013;140(3):258–66.
17. Zhao K et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682–90.
18. Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HHJ. Pharmacol Exp Ther. 2003;304:425–32.
19. Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–61.
20. Birk AV, Chao WM, Liu S, Soong Y, Szeto HH. Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia. Biochim Biophys Acta. 2015;1847(10):1075–84.
21. Han Z, Varadharaj S, Giedt RJ, Zweier JL, Szeto HH, Alevriadou BR. Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells. J Pharmacol Exp Ther. 2009;329(1):94–101.
22. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011;16(3–4):244–50.
23. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296–303.